United Asset Strategies’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

United Asset Strategies’s Portfolio CELGZ Stock Details CELGZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-112,300	Closed	-$121K	–	164
2017 Q1	$121K	Hold	112,300	–	–	0.04%	142
2016 Q4	$116K	Hold	112,300	–	–	0.04%	144
2016 Q3	$117K	Hold	112,300	–	–	0.04%	135
2016 Q2	$164K	Buy	+112,300	New	+$145K	0.06%	135

Other funds holding CELGZ

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

MSTVIM

Messner & Smith Theme Value Investment Management San Diego, California $60.3M AUM 16.8% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

United Asset Strategies's CELGZ Position: Q2 2017 in Review

United Asset Strategies sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q2 2017, closing a stake of 112,300 shares — an estimated $121K sold.

United Asset Strategies first reported a position in CELGZ in Q2 2016 and held it in 4 quarters. The position peaked at $164K in Q2 2016. 21 funds tracked by Wall St. Rank hold CELGZ as of Q2 2017.

United Asset Strategies reported no remaining Celgene Corporation Contingent Value Rights position as of Q2 2017 after selling out during the quarter.
United Asset Strategies sold 112,300 Celgene Corporation Contingent Value Rights shares in Q2 2017, an estimated $121K.
United Asset Strategies first reported a position in Celgene Corporation Contingent Value Rights in Q2 2016 and held it in 4 quarters.
United Asset Strategies's Celgene Corporation Contingent Value Rights position peaked at $164K in Q2 2016.
21 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q2 2017.

Based on United Asset Strategies's 13F filing for Q2 2017, filed 2 Aug 2017.